AGN - Allergan plc

NYSE - Nasdaq Real Time Price. Currency in USD
+0.03 (+0.02%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close192.99
Bid0.00 x 900
Ask0.00 x 1100
Day's Range191.64 - 193.37
52 Week Range114.27 - 202.22
Avg. Volume4,826,652
Market Cap63.659B
Beta (5Y Monthly)1.20
PE Ratio (TTM)N/A
EPS (TTM)-7.57
Earnings DateAug 04, 2020 - Aug 10, 2020
Forward Dividend & Yield2.96 (1.53%)
Ex-Dividend DateApr 15, 2020
1y Target Est188.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • How Hedge Funds Traded Allergan plc (AGN) Before Its Acquisition
    Insider Monkey

    How Hedge Funds Traded Allergan plc (AGN) Before Its Acquisition

    At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]

  • John Paulson Trims Allergan, Sprint, Discovery

    John Paulson Trims Allergan, Sprint, Discovery

    Firm's largest sales of the 1st quarter Continue reading...

  • Bull of the Day: AbbVie (ABBV)

    Bull of the Day: AbbVie (ABBV)

    Bull of the Day: AbbVie (ABBV)

  • Jim Simons' Top Buys of the 1st Quarter

    Jim Simons' Top Buys of the 1st Quarter

    Founder of Renaissance Technologies releases portfolio update Continue reading...

  • After Drug Failure, Genfit's Cupboard Is Nearly Bare

    After Drug Failure, Genfit's Cupboard Is Nearly Bare

    Company’s high hopes for NASH drug stymied, providing opening for Intercept Pharma treatment Continue reading...

  • Is AbbVie a Buy Now That the Allergan Deal Is Done?
    Motley Fool

    Is AbbVie a Buy Now That the Allergan Deal Is Done?

    Allergan brings quite a bit to the table for AbbVie. But is it enough to make the big pharma stock a smart pick right now?

  • AbbVie Is a Buy as Allergan Deal Closes - A Look at the Charts

    AbbVie Is a Buy as Allergan Deal Closes - A Look at the Charts

    AbbVie is rallying now that the company has closed its mega-deal with Allergan. The stock is looking to possibly test 2020 highs.


    AbbVie Gets Favorable Analyst Reviews After Allergan Merger

    AbbVie gets an overweight rating from Morgan Stanley but SVB Leerink, which has the same rating, raised its price target.

  • The Reasons to Be in AbbVie: Valuation, Dividend Yield, Confidence in Guidance

    The Reasons to Be in AbbVie: Valuation, Dividend Yield, Confidence in Guidance

    How long ago was it that we were writing about how much we liked the aggression shown by AbbVie management in addressing the threat posed by the the expiration of patents concerning Humira, the firms' leading selling product. Humira, a treatment for rheumatoid arthritis, Crohn's disease, and a number of other maladies, has been the firm's cash cow, really since the split from Abbot Laboratories back in early 2013. What AbbVie had done, about a year ago now, was address the potential hole in cash flow potentially created by generic competition for Humira, and to proceed with a deal to acquire Allergan , another cash flow machine, with a cash cow of its own in Botox.

  • AbbVie Wraps Its $63 Billion Allergan Buyout — Is AbbVie Stock A Buy?
    Investor's Business Daily

    AbbVie Wraps Its $63 Billion Allergan Buyout — Is AbbVie Stock A Buy?

    AbbVie stock recently broke out and the pharmaceutical company just wrapped its acquisition of Allergan. Is AbbVie stock a buy now?

  • MarketWatch

    AbbVie closes acquisition of Allergan

    Allergan PLC said late Friday that AbbVie Inc. has closed its acquisition of the company. On Tuesday, the companies announced the deal had cleared U.S. antitrust conditions. Back in June, AbbVie announced it would acquire Allergan for about $62 billion. AbbVie shares rose 0.6% after hours while Allergan shares advanced 0.5%.

  • AbbVie Inc. Completes Acquisition of Allergan plc
    PR Newswire

    AbbVie Inc. Completes Acquisition of Allergan plc


  • Editas' (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y

    Editas' (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y

    Editas (EDIT) beats on earnings in the first quarter of 2020 while revenues slightly miss estimates.

  • Ironwood (IRWD) Misses Q1 Earnings and Revenue Estimates

    Ironwood (IRWD) Misses Q1 Earnings and Revenue Estimates

    Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. COVID-19 impacts enrollment in clinical studies.

  • The Allergan Foundation Doubles its COVID-19 Response Donations to $4.0 Million
    PR Newswire

    The Allergan Foundation Doubles its COVID-19 Response Donations to $4.0 Million

    Allergan plc (NYSE: AGN) today announced that The Allergan Foundation has fast-tracked another $2 million dollars in charitable grants for community organizations responding to the COVID-19 pandemic. The new grants double The Allergan Foundation's total COVID-19 donations to date, raising the total to $4 million. The donations are dedicated to 57 organizations working on the front lines of the community response to the pandemic in New York, New Jersey, California, Texas, Ohio, Florida and internationally.

  • DexCom & Domino's Pizza Set to Join S&P 500; to Join S&P 100; STORE Capital to Join S&P MidCap 400; Capri Holdings to Join S&P SmallCap 600
    PR Newswire

    DexCom & Domino's Pizza Set to Join S&P 500; to Join S&P 100; STORE Capital to Join S&P MidCap 400; Capri Holdings to Join S&P SmallCap 600

    S&P; Dow Jones Indices will make the following changes to the S&P; 500, S&P; 100, S&P; MidCap 400, and S&P; SmallCap 600 effective prior to the opening on Tuesday, May 12:

  • Reuters

    Domino's Pizza to join S&P 500, despite pandemic's impact

    Domino's Pizza Inc will join the Standard & Poor's 500, despite having last month withdrawn its long-term growth outlook after closing stores because of the coronavirus pandemic. S&P Dow Jones Indices said on Wednesday it is promoting the Ann Arbor, Michigan-based pizza delivery chain from its S&P MidCap 400, one of several changes it announced to its indexes. While withdrawing its forecast for two- to three-year sales growth, Domino's said U.S. same-store sales were up 7.1% in late March and much of April, as diners under lockdown ordered home delivery more often.

  • AbbVie's Pending Acquisition of Allergan Earns FTC Approval
    Motley Fool

    AbbVie's Pending Acquisition of Allergan Earns FTC Approval

    With this final regulatory sign-off, the deal between these two pharmaceutical giants should close very soon.

  • The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

    The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5)• Adverum Biotechnologies Inc (NASDAQ: ADVM) ( reacted to a positive clinical readout) • Akebia Therapeutics Inc (NASDAQ: AKBA) (announced positive topline results for a late-stage study of drug to treat anemia in chronic kidney disease patients) • BIO-TECHNE Corp (NASDAQ: TECH) • ChemoCentryx Inc (NASDAQ: CCXI) • Cytokinetics, Inc. (NASDAQ: CYTK) • DexCom, Inc. (NASDAQ: DXCM) • GenMark Diagnostics, Inc (NASDAQ: GNMK)(announced strong quarterly results) • Immunomedics, Inc. (NASDAQ: IMMU) • Immunovant Inc (NASDAQ: IMVT) • Masimo Corporation (NASDAQ: MASI) • Minerva Neurosciences Inc (NASDAQ: NERV) • ORIC Pharmaceuticals Inc (NASDAQ: ORIC) • Regeneron Pharmaceuticals Inc (NASDAQ: REGN)(reported quarterly results and announced positive results for its immuno-oncology therapy in treating skin cancer) • Seattle Genetics, Inc. (NASDAQ: SGEN) • TG Therapeutics Inc common stock (NASDAQ: TGTX)(announced positive late-stage readout for combo therapy in treating chronic lymphocytic leukemia) • Vermillion, Inc. (NASDAQ: VRML) • Zynex Inc. (NASDAQ: ZYXI)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 5)• Biofrontera AG (NASDAQ: BFRA) • Lyra Therapeutics Inc (NASDAQ: LYRA) (IPOed May 1)Stocks In Focus AstraZeneca's Farxiga Gets Label Expansion to Treat Heart Failure AstraZeneca plc (NYSE: AZN) announced FDA approval for Farxiga oral tablets for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure.In after-hours trading, the stock edged up 0.52% to $53.75.AbbVie Gets Antitrust Clearance For Allergan Buy AbbVie Inc (NYSE: ABBV) and Allergan plc (NYSE: AGN) announced they have received clearance from the FTC for the pending acquisition of the latter by the former. The clearance was obtained following Allergan's decision to divest its autoimmune disorder treatment brazikumab to AstraZeneca as well as exocrine pancreatic insufficiency therapy Zenpep and another pancreatic enzyme preparation to Nestle S.A. (OTC: NSRGY).Allergan has also decided that only one of its directors will join AbbVie board, and the companies have amended the transaction agreement accordingly. The closing of the deal is now contingent on the Irish High Court approval. A hearing for the same is scheduled today.See Also: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates Qiagen Expects Q2 Results Above Consensus; Suspends Guidance Qiagen NV (NYSE: QGEN) pre-announced second-quarter results, expecting net sales growth of at least 12% at constant exchange rates and adjusted earnings per share of at least 40 cents at CER. The company said the sales growth for the quarter is likely to have benefited from the ongoing significant demand for various products and solutions in pandemic testing, partly offset by lower sales in other areas of its portfolio.The company also suspended its full-year outlook. It is scheduled to release its first-quarter results after the close.Cidara Announces Positive Data For Anti-fungal and Anti-viral Candidates Cidara Therapeutics Inc (NASDAQ: CDTX) announced publication of 10 abstracts reporting new clinical and preclinical data on the Company's antifungal rezafungin program and preclinical data on its Cloudbreak antiviral program that was to be present at the now cancelled European Congress of Clinical Microbiology and Infectious Diseases 2020 meeting.Data from the STRIVE Phase 2 trial showed that a single dose of rezafungin has a Day 5 success rate of 62.3% compared to 55.7% for the approved echinocandin comparator, caspofungin. Additionally, preclinical data in a rabbit model of Candida endophthalmitis showed treatment with rezafungin significantly lowered fungal burden as compared to micafungin, azole as well as vehicle control in multiple eye tissues.New findings on the company's Cloudbreak antiviral platform candidate CD377 showed the candidate's tolerability and stability in preclinical invitro and invivo studies. In animal testing, single doses of CD377 showed a greater decrease in lung viral burden and cytokine levels compared to oseltamivir, dosed for five days.The stock added 3.68% to $3.10 in after-hours trading.Offerings Kura Oncology Inc (NASDAQ: KURA) said it has commenced an underwritten public offering to sell shares of its common stock.In after-hours trading, the stock fell 1.03% to $14.46.Silk Road Medical Inc (NASDAQ: SILK) said it has priced an underwritten public offering of 6.81 million shares of its common stock at $39 per share. About 4.89 million shares are being offered by the company and the remaining 1.92 million by certain selling shareholders. The company expects to generate gross proceeds of about $75 million from the offering. The offering is expected to close May 8.The stock fell 7% to $40.25 in after-hours trading.Earnings Supernus Pharmaceuticals Inc's (NASDAQ: SUPN) first-quarter revenues rose 11% to $95 million, ahead of the $83.48 million consensus estimate, and earnings per share, or, EPS, came in at 40 cents compared to the Street estimate of 28 cents. The company suspended its full-year guidance.The stock jumped 22.69% to $27.20 in after-hours trading.View more earnings on IBBClovis Oncology Inc (NASDAQ: CLVS) reported Rubraca product revenues of $42.6 million compared to the consensus estimate of $41.41 million. The net loss, however, came in wider than expectations at $1.39 per share.The stock gained 9.73% to $8.46 in after-hours trading.Axonics Modulation Technologies Inc (NASDAQ: AXNX) reported first-quarter revenues of $26.3 million, way ahead of the consensus of $15.16 million. The loss per share came in at 43 cents compared to the 61-cents consensus estimate. In after-hours trading, the stock was up 7.42% to $35.75.Myriad Genetics, Inc. (NASDAQ: MYGN) reported below-consensus revenues and an unexpected loss for its first quarter.The stock slipped 8.13% to $13.61 in after-hours trading.Jazz Pharmaceuticals PLC's (NASDAQ: JAZZ) first-quarter revenues climbed 5% to $535 million, trailing estimates of $544.55 million. The adjusted EPS came in at 45 cents, below the consensus estimate of 67 cents. The company lowered its full-year guidance.In after-hours trading, the stock slipped 6.26% to $103.50.Cytosorbents Corp (NASDAQ: CTSO) reported first-quarter revenues of $8.7 million compared to the average analysts' estimate of $7 million. The loss came in at 10 cents per share compared to the 13 cents per share loss estimated by analysts. The company also hinted at higher second-quarter revenues relative to the first quarter, thanks to CytoSorb, which is used as a treatment of cytokine storm in many countries worldwide.The stock gained 7.52% to $10.01 in after-hours trading.T2 Biosystems Inc (NASDAQ: TTOO) reported below-consensus first-quarter revenues and a wider-than-expected loss.The stock slumped 9.67% to 54 cents in after-hours trading.Agile Therapeutics Inc (NASDAQ: AGRX) reported a wider-than-expected first-quarter loss.In premarket trading, the stock declined 9.19% to $2.57.Danish diabetes drug company Novo Nordisk A/S (NYSE: NVO) said its first-quarter sales as well as EPS climbed 16%, thanks to pandemic-related stocking.On The Radar Axcella Health Inc (NASDAQ: AXLA) is due to announce top-line data from a study that is assessing the impact of AXA1125 and AXA1957 on safety, tolerability and effects on structures and functions of the liver in adult subjects with nonalcoholic fatty liver disease, or NAFLD.Earnings • Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) (before the market open) • Horizon Therapeutics PLC (NASDAQ: HZNP) (before the market open) • Constellation Pharmaceuticals Inc (NASDAQ: CNST) (before the market open) • Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) (before the market open) • IVERIC bio Inc (NASDAQ: ISEE) (before the market open) • Blueprint Medicines Corp (NASDAQ: BPMC) (before the market open) • BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) (before the market open) • Strongbridge Biopharma plc (NASDAQ: SBBP) (before the market open) • Evofem Biosciences, Inc. (NASDAQ: EVFM) (before the market open) • Neurocrine Biosciences, Inc. (NASDAQ: NBIX) (before the market open) • Jounce Therapeutics Inc (NASDAQ: JNCE) (before the market open) • PPD Inc (NASDAQ: PPD) (before the market open) • Zoetis Inc (NYSE: ZTS) (before the market open) • Ionis Pharmaceuticals Inc (NASDAQ: IONS) (before the market open) • TherapeuticsMD Inc (NASDAQ: TXMD) (before the market open) • Avanos Medical Inc (NYSE: AVNS) (before the market open) • Aerie Pharmaceuticals Inc (NASDAQ: AERI) (after the close) • Allogene Therapeutics Inc (NASDAQ: ALLO) (after the close) • ADMA Biologics Inc (NASDAQ: ADMA) (after the close) • Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) (after the close) • AxoGen, Inc Common Stock (NASDAQ: AXGN) (after the close) • Global Blood Therapeutics Inc (NASDAQ: GBT) (after the close) • Pacific Biosciences of California (NASDAQ: PACB) (after the close) • Theravance Biopharma Inc (NASDAQ: TBPH) (after the close) • BioTelemetry Inc (NASDAQ: BEAT) (after the close) • Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) (after the close) • Veracyte Inc (NASDAQ: VCYT) (after the close) • Ligand Pharmaceuticals Inc. (NASDAQ: LGND) (after the close) • Precigen Inc (NASDAQ: PGEN) (after the close) • Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (after the close) • OraSure Technologies, Inc. (NASDAQ: OSUR) (after the close) • NuVasive, Inc. (NASDAQ: NUVA) (after the close) • Sarepta Therapeutics Inc (NASDAQ: SRPT) (after the close) • Natera Inc (NASDAQ: NTRA) (after the close) • Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) (after the close) • Qiagen NV (NYSE: QGEN) (after the close) • Enanta Pharmaceuticals Inc (NASDAQ: ENTA) (after the close) • Esperion Therapeutics Inc (NASDAQ: ESPR) (after the close) • G1 Therapeutics Inc (NASDAQ: GTHX) (after the close) • Quidel Corporation (NASDAQ: QDEL) (after the close) • Cytokinetics (after the close) • MannKind Corporation (NASDAQ: MNKD) (after the close) • Atara Biotherapeutics Inc (NASDAQ: ATRA) (after the close) • Cellular Biomedicine Group Inc (NASDAQ: CBMG) (after the close) • Opko Health Inc. (NASDAQ: OPK) (after the close) • VIVUS, Inc. (NASDAQ: VVUS) (after the close) • Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (after the close) • Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) (after the close)See more from Benzinga * The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace(C) 2020 Benzinga does not provide investment advice. All rights reserved.

  • Announcement relating to the outcome of the Court Sanction Hearing
    PR Newswire

    Announcement relating to the outcome of the Court Sanction Hearing


  • AbbVie Scores US Antitrust Approval for $63B Allergan Deal

    AbbVie Scores US Antitrust Approval for $63B Allergan Deal

    AbbVie’s (ABBV) plan to close the $63 billion Allergan (AGN) deal this month appears on track following the announcement that they have received US Federal Trade Commission (FTC) clearance for the deal.The acceptance of the proposed consent order by the FTC satisfies all the required antitrust clearances needed for AbbVie to buy Allergan.As part of the proposed consent, Allergan has agreed to divest brazikumab, an investigational IL-23 inhibitor in development for autoimmune diseases, to AstraZeneca (AZN).Plus it will sell Zenpep, a treatment for exocrine pancreatic insufficiency due to cystic fibrosis and other conditions, to Nestle. Nestle will also acquire Viokace, another pancreatic enzyme preparation, as part of the same transaction.Additionally, AbbVie and Allergan have amended the Transaction Agreement to allow only one Allergan Director will join the AbbVie board following close. Allergan’s current Chairman and CEO Brent Saunders will not join the AbbVie Board in order to pursue other opportunities, the press release revealed.Going forward, the acquisition is still subject to other customary closing conditions and Irish High Court approval- with a hearing scheduled for today May 6.Mizuho Securities’ Vamil Divan gives the deal his seal of approval. A key concern surrounding the Allergan deal has been whether the FTC might require AbbVie to divest its key growth driver Skyrizi, says Divan. “This investor concern should finally be allayed, as the FTC appears satisfied with the divestiture of Allergan’s brazikumab (IL-23) back to AstraZeneca instead” the analyst wrote.He continues to see AbbVie as a ‘top large-cap pick’ and believes the Allergan deal changes the AbbVie story for the better. “It brings in additional growth drivers at an attractive price, including products early in their life cycle (e.g. Vraylar, Ubrelvy) and others that should be highly durable (e.g. Botox, Juvederm), as well as >$2Bn in expense synergies” Divan told investors on May 5.Indeed, the stock boasts a firmly bullish Strong Buy Street consensus with an average analyst price target of $100 (17% upside potential). That falls just under Divan’s own price target of $101. (See AbbVie stock analysis on TipRanks)Related News: Akebia Spikes 38% On Pivotal Trial Readout; And Further Upside Lies Ahead Novavax (NVAX) Receives Bullish Praise From a Wall Street Pro Spotify Stock at $190 a Share? This Top Analyst Thinks It’s Possible More recent articles from Smarter Analyst: * CyberArk Software Shares Sink 6% on Weak Sales Outlook * Uber Announces $750M Notes Offering, As GrubHub Takeover Reports Swirl * Twitter Won’t Reopen Offices Before Sept., Allows Permanent Work From Home * Waymo Raises $3 Billion In Extended Financing Round

  • AbbVie wins U.S. antitrust approval to buy Allergan

    AbbVie wins U.S. antitrust approval to buy Allergan

    Drugmaker AbbVie Inc <ABBV.N> has won U.S. antitrust approval to buy Botox maker Allergan <AGN.N>, a blockbuster $63 billion deal when it was announced last year, the companies said on Tuesday. AbbVie, which has been under pressure to diversify its portfolio, said in June 2019 that it would acquire Allergan in a deal that gives AbbVie control over the lucrative wrinkle treatment Botox and buys time to seek new growth before its arthritis treatment Humira loses U.S. patent protection in 2023. The combined AbbVie and Allergan will be based in AbbVie's home of North Chicago.

  • MarketWatch

    Abbvie's deal for Allergan clears U.S. antitrust hurdle

    The deal for AbbVie Inc. to buy Allergan Plc. has cleared an antitrust hurdle, the companies said late Tuesday. The U.S. Federal Trade Commission has accepted a proposed consent order in connection with the pending acquisition, satisfying "all required antitrust clearances needed" for the deal, they said. As part of order, Allergan has agreed to sell some treatments to AstraZeneca Plc. and Nestle SA . The two companies also said they have amended their agreement to stipulate that only one Allergan director will join the AbbVie board after the close. Allergan's current Chairman and Chief Executive Brent Saunders has elected not to join the AbbVie board "to provide more flexibility to pursue other opportunities in the sector," the companies said. The deal's closing remains subject to other closing conditions, including a hearing in Ireland on Wednesday.